Stock Analysis·← Pickers

SNY

Sanofi

Sanofi (SNY) is currently in a range/mixed trend, above the 50-day MA but below the 200-day MA. RSI is at 52.6, with 1/3 trend checks passing.

Price
$43.68
+0.50 (+1.16%)
Day range
$43.03–$43.74
52wk $40.89–$52.68
Volume
2.0M
Avg
Trend score
1/3
Range / Mixed
RSI (14)
52.6
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

SNY with MA50 and MA200

52.3449.5946.8444.0841.3307/3110/2401/2204/1707/15
SNY2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$43.31+0.85% vs price
MA200
$46.78-6.64% vs price
RSI (14)
52.6Neutral zone
MACD Signal
BullishMomentum above signal
Macro Support
Not identifiedNo repeated weekly support zone found
Support Quality
Volume data unavailable
Valuation

SNY valuation multiples (TTM)

P/E Ratio
P/S Ratio
P/B Ratio
EV/EBITDA
Valuation multiples are provided by Financial Modeling Prep when available.
Analyst Ratings

SNY analyst consensus

Avg Price Target
High Target
Low Target
Analyst Coverage
Analyst ratings and price targets are provided by Financial Modeling Prep when available.
Chart Summary
Trend summary for SNY

Sanofi (SNY) currently looks more uncertain than directional, with a fairly mixed technical picture. The latest available price is $43.68, and 1 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 0.9% and below the 200-day moving average by 6.6%.

Momentum and stretch context

SNY currently has an RSI reading of 52.6, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.

What traders may watch next

This page is designed to help you quickly understand what the SNY chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.

Company profile

About Sanofi

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Belén Garijo López
Employees
82,878
Market cap
$105.38B
Beta
0.28
52-week range
$40.89 – $52.68
Dividend
Yes · $2.42
Exchange
NASDAQ
Country
FR
IPO date
1 Jul 2002
ISIN
US80105N1054
CUSIP
80105N105
Website
sanofi.com
Company profile data from Financial Modeling Prep. SNY listed on NASDAQ.
Share dilution

SNY shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Jun 2019Mar 2026
Shares outstanding (latest)
2.41B
Since Jun 2019
-3.6%
Trend
Fewer shares outstanding (buybacks)
Historical shares-outstanding data from Financial Modeling Prep. SNY28 data points from Jun 2019 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about SNY

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.